Baxter International arrives at its April 30 Q1 earnings call carrying a stock down 3% on the week and a history of painful post-print selloffs — yet short sellers quietly pulled back just as the pressure approached.
The most striking move in the data is that sharp retreat in short interest. Short interest dropped roughly 7% across the week, falling from around 40.5 million shares to 37.6 million. That brings SI to 7.3% of the free float — still meaningfully elevated, but well off the mid-April highs. The timing matters: shorts trimmed exposure into a known earnings event, suggesting the aggressive bear thesis has at least partially been taken off the table ahead of the release. The borrow market reinforces a relaxed picture. Cost to borrow is running below 0.5% annually — barely above the risk-free rate — and has been effectively flat for six weeks. Availability of shares to borrow remains ample; the lending pool is nowhere near stretched, with the 52-week peak in utilization sitting at 44.3% versus the current 30.8%. There is no squeeze pressure here.
Options traders, meanwhile, lean modestly bullish — or at least less defensive than usual. The put/call ratio is 0.66, sitting half a standard deviation below its 20-day average of 0.76. That's a notable pivot from early April, when the PCR ran above 1.0 through most of the tariff-driven volatility. Call demand has picked up relative to puts in recent sessions. The contrast with the short interest picture is consistent: whatever nervousness existed around macro risk in early April has faded somewhat, and options traders are not loading up on downside protection ahead of the print.
The Street remains in a holding pattern. Analysts have spent the past several months in almost unbroken target-cutting mode, with Goldman Sachs, Citi, Barclays, Morgan Stanley, and Evercore ISI all reducing price targets since October. The direction of travel has been uniformly lower — but the underlying ratings have barely moved, with most firms staying at Neutral or Overweight rather than capitulating to Sell. The mean price target sits near $22, roughly 23% above the current price of $17.94. Barclays retains Overweight with a $25 target; Morgan Stanley anchors the bear end with Underweight and a $15 target. Valuation has compressed alongside the price: the P/E multiple is around 9.2x and EV/EBITDA near 8.3x, both having drifted lower over the past 30 days as the stock gave back some of its month-long 12% gain. The forward EPS trajectory earns a decent rank — top-quarter for 12-month forward growth — but near-term momentum is weak, with EPS surprise ranking in just the 5th percentile.
The earnings history is where the real caution lives. The last three prints produced declines of 0.4%, 11.1%, and 17.6% on the day respectively — a brutally consistent record of post-announcement selling. The five-day outcomes have also been negative across the board. That pattern sets the context for Thursday's print: it is not a stock that has rewarded bulls on results day. Institutional ownership tells a different story about patience, with BlackRock, Pzena, Vanguard, and Dodge & Cox together holding over 50% of shares, and Fidelity adding nearly 14 million shares as of March 31. Those are holders who appear to be waiting for a longer-term recovery thesis rather than trading the print. Insider activity has been entirely on the sell side since February, with the CFO and multiple senior vice presidents selling at prices between $17.69 and $21.73 through early March — though the volumes were modest and the significance scores low, suggesting routine vesting-related activity rather than conviction selling.
Heading into Wednesday's close, the setup is one of reduced but not eliminated short positioning, relaxed borrow conditions, a mildly constructive options tilt, and a Street that has stopped cutting targets aggressively but not yet started raising them. What matters most on April 30 is whether management can break the pattern of disappointing on margins and guidance — three quarters of negative day-one reactions mean the bar for a neutral outcome is set uncomfortably high.
See the live data behind this article on ORTEX.
Open BAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
